BRAF and thyroid cancer: Unfortunately, five single-arm (6, 7, 14, 22, 23) and three uncontrolled retrospective studies (24, 25, 26) on MAPK inhibition of metastatic RAI-resistant thyroid cancer with BRAF, RAS, or no detected driver mutation for RAI re-sensitization do not provide any information regarding TERT mutation analysis.